# Beta lactam antibiotics, a process for their preparation and their use in pharmaceutical compositions.

## Abstract
The present invention relates to carbapenem derivatives, and, in particular, to a novel class of substituted carbapenem derivatives wherein the C 6 substituent is a substituted triazolyl ethyl group. The present invention provides a compound of the formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof CHEM wherein R 1 is hydrogen, an organic radical or group S O nR 2 wherein R 2 an organic radical and n is zero or one and A is a divalent two atom radical forming the residue of a five membered ring wherein one of the atoms is optionally substituted carbon and the second atom is an optionally substituted carbon or nitrogen atom.

## Claims
Claims 1. A compound of the formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI37.1 wherein RÚ is hydrogen, an organic radical or group S O nR wherein R2 an organic radical and n is zero or one and A is a divalent two atom radical forming the residue of a five membered ring wherein one of the atoms is optionally substituted carbon and the second atom is an optionally substituted carbon or nitrogen atom 2. A compound as claimed in claim 1 wherein the divalent two atom radical A completes an optionally mono or disubstituted triazole or dihydrotriazole ring. 3. A compound as claimed in claim 1 or claim 2 wherein the divalent two atom radical A completes a mono or di substituted triazole ring. 4. A compound as claimed in any one of claims 1 to 3 wherein R1 is acetamidoethylthio or acetamidoethenyl thio. 5. A compound as claimed in any one of claims 1 to 4 whereon the hydrogen atoms at the C S and C 6 carbon atoms are in the trans configuration with the configuration 5R, 6S. 6. A compound as claimed in any one of claims 1 to 4 wherein the hydrogen atoms at the C S and C 6 carbon atoms are in the cis configuration with the configuration SR, 6R. 7. A compound as claimed in any one of claims 1 to 6 having formula II or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI38.1 wherein R1 is as defined in claim 1 and B is a divalent radical of structure EMI38.2 wherein R represents a carboxylic acid group or an ester or amide derivative thereof or a nit rile group and R represents hydrogen, an optionally substituted hydrocarbon or heterocyclic group, a carboxylic acid group or an ester or amide derivative thereof or a nitrile group. 8. A compound as claimed in claim 7 wherein R3 is a carboxylic acid group, or a salt, or methyl, ethyl, p nitrobenzyl, 2 amino ethyl or 2 p nitrobenzyloxycarbonyl amino ethyl ester thereof. 9. A compound as claimed in claim 7 or claim 8 wherein R is hydrogen. 10. A pharmaceutical composition which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable carrier. 11. A process for the preparation of a compound as claimed in claim 1 which process comprises reacting a compound of formula III EMI39.1 wherein R1 is as defined with respect to formula I and wherein any reactive groups may be protected and R is a carboxy protecting group. with a dipolarophile, and thereafter where necessary carrying out one or more of the following steps i removing any protecting groups on R , or the dipolarophile, ii removing the carboxy protecting group Rx, iii converting a free acid to an in vivo hydrolysable ester or a ph maceutically acceptable salt. 12. A compound of formula VIII or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI40.1 wherein R1is as defined with respect to formula I hereinbefore and R8 is an azido or amino group9

## Description
ss Lactam Antibiotics, a process for their preparation and their use in pharmaceutical compositions The present invention relates to carbapenem derivatives, and, in particular, to a novel class of substituted carbapenem derivatives wherein the C 6 substituent is a substituted triazolyl ethyl group.This invention further relates to processes for their preparation and to compositions containing them. These derivatives are of use in the treatment of bacterial infection. Accordingly, the present invention provides a compound of the formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI1.1 wherein R is hydrogen, an organic radical or group s o R 2 n wherein R an organic radical and n is zero or one and A is a divalent two atom radical forming the residue of a five membered ring wherein one of the atoms is optionally substituted carbon and the second atom is an optionally substituted carbon or nitrogen atom. Suitably the divalent two atom radical completes an optionally mono substituted triazole, tetrazole, dihydrotriazole, dihydrotetrazole, or a disubstituted triazole or dihydrotriazole ring. More suitably the divalent two atom radical completes a mono or di substituted triazole or dihydrotriazole ring. Preferably the divalent two atom radical completes a mono or di substituted triazole ring. Suitably the substituent will be a conjugating group, such as, for example, a carboxylic acid group or an ester or amide derivative thereof or a nitrile group. Suitable compounds of formula I include those wherein R1 is hydrogen, methyl, ethyl, n or iso propyl or n , sec , tert or iso butyl. Further suitable compounds of formula I are those wherein RÚ is a group of formula SRê wherein Rê is C1 6 alkyl, C2 6 alkenyl, C2 6 alkynyl, aryl, or a heterocyclyl, heterocyclyl C1 6 alkyl, heteroaryl C1,6 alkyl or heteroaryl group wherein the hetero atom or hetero atoms in the above named heteroaryl and or heterocycyl moieties are selected from 1 4 oxygen, nitrogen or sulphur atoms any of such Rê groups being optionally substituted. R 2. When R is a C1 6 alkyl group suitable substituents include amino, di C1 6 alkylamino, C1 6 alkylamino, acylamino, hydroxy, C1 6 alkanoyloxy, C1 6 alkoxy, benzoyl,C1 6 alkanoyl or carboxy or an ester or salt thereof. More suitably such alkyl groups contain up to 4 2 carbon atoms, for example R aptly may be methyl, ethyl, propyl, butyl, aminoethyl, aminopropyl aminobutyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl, propoxypropyl, methoxypropyl, methoxybutyl, acetoxymethyl, acetoxyethyl, propionoxymethyl, propionoxyethyl, phenacyl, acetylmethyl, acetylethyl, propionylmethyl, propionylethyl, carboxymethyl or pharmaceutically acceptable salt thereof, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, methoxycarbonylpropyl, methoxycarbonylbutyl, ethoxycarbonylethyl, carboxyethyl or pharmaceutically acceptable salt thereof, carboxypropyl or pharmaceutically acceptable salt thereof, carboxybutyl or pharmaceutically acceptable salt thereof, acetamidoethyl and propionamidoethyl.Of these values methyl, ethyl, propyl, butyl, 2 aminoethyl and acetamidoethyl are preferred. 2 When R2 is a C2 6 alkenyl group wherein the double bond is not present on the carbon adjacent to the sulphur atom, suitable substituents include carboxy or an ester or pharmaceutically acceptable salt thereof, or hydroxy orC1 6 alkoxy. When Rê is a C2 6 alkenyl group wherein the double bond is present on the carbon adjacent to the sulphur atom, suitable substituents include carboxy or an ester or pharmaceutically acceptable salt thereof. 2 More suitably R is propenyl, butenyl and CH CH C02H or a pharmaceutically acceptable salt or ester thereof, for example the sodium or potassium salt or the methyl, ethyl, propyl, aminoethyl, aminopropyl, benzyl or p nitrobenzyl ester. In another aspect preferred values for RI include the acetamidoethenyl and propionamidoethenyl groups. Suitable aryl, heteroaryl and heterocyclyl groups 2 for use in the substituent R include phenyl, naphthyl, pyrrolyl, furyl, tetrazolyl, thienyl, indolyl, thionaphthyl, benzofuryl, imidazolyl, thiazolyl, or any of such groups substituted by one or more groups selected from C13 alkyl, phenyl, nitro and amino or a phenyl group optionally substituted by halogen atom or a C 1 3 alkoxy, nitro or acetamido group. 2 When R is an aryl C1 6 atkyl, heteroaryl C1 6 alkyl or heterocyclyl C1 6 aryl group, more suitably the alkyl moiety is a methylene or ethylene divalent radical.Suitable examples of such aryl and heteroaryl moieties are phenyl optionally substituted by one or more substituents selected from a halogen atom or a C1 3 alkoxy, nitro or acetamido group pyrrolyl optionally substituted by a phenyl or C 1 3 alkyl group thienyl optionally substituted by a phenyl or C13 alkyl group furyl optionally substituted by a phenyl or C1 3 alkyl group tetrazolyl optionally substituted by phenyl or a C13 alkyl group imidazolyl optionally substituted by one or more groups selected from phenyl, nitro, amino, C1 3 alkyl and thiazolyl optionally substituted by one or more groups selected from phenyl, nitro, amino and C1 3 alkyl. More suitably R 2 is a benzyl, bromobenzyl, chlorobenzyl, flurobenzyl, methoxybenzyl, nitrobenzyl, acetamidobenzyl, thiazolylmethyl, aminothiazolymethyl, nitrothiazolymethyl or phenylthiazolylmethyl group. Suitably also R is a phenethyl, pyrrolylethyl or optionally substituted tetrazolylethyl or imidazolylethyl. In a suitable aspect the imidazolyl ring may be substituted at the C 2 position that is the carbon atom a to the two nitrogen atoms by a C13 alkyl or phenyl group. In another aspect the imidazolyl ring may be further substituted at the C 4 position or the C S position by a C13 alkyl, phenyl, nitro or amino groups preferably such substituents are on the C 4 position and the C S position is unsubstituted alternatively such substituents are on the C S position and the C 4 position is unsubstituted. In a further aspect Rê is a C16 alkanoyl, aralkanoyl, aroxyalkanoyl or aroyl group, for example acetyl, phenylacetyl, phenoxyacetyl or benzoyl. Of these acetyl is preferred. Suitably R 2 is phenyl optionally substituted by a halogen atom or a C13 alkyl, C13 alkoxy, nitro or acetamido group. Suitably R 2 is a 5 or 6 membered aromatic heterocyclic group containing 1 or 2 nitrogen atoms such as the pyridyl, pyrimidyl, pyrrolyl and imidazoyl ring systems, for example 2 pyridyl, 3pyridyl, 4 pyridyl, 2 pyrimidinyl, 4 pyrimidinyl, 5pyrimidinyl, 2 pyrrolyl, 3 pyrrolyl, 2 imidazolyl and 4 imidazolyl. Of these the pyridyl and pyrimidinyl ring systems are favoured, the pyrimidinyl ring being preferred and in particular the 2 pyrimidinyl and 4pyrimidinyl ring systems. Suitably such aromatic heterocyclic ring systems are optionally substituted by one or more C1 4 alkyl or C1 4 alkanoyloxy groups. Suitable salts of the compounds of formula I include salts e.g. aluminium, alkali metal salts such as sodium or potassium alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy lower alkylamines such as 2 hydroxyethylamine, bis 2 hydroxyethyl amine or tri 2 hydroxyethyl amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylamine, N,N dibenzlethylenediamine, 1 ephenamine, N ethylpiperidine, N benzyl ss phenethylamine, dehydroabietylamine, N,NÚ bisdehudroabietylamine, ethylenediamine, or bases of the pyridine type such as pyndine, collidine, or quinoline. Suitable in vivo hydrolyzable esters of the compound of formula I include acyloxyalkyl groups such as acetoxymethyl, pivaloyloxymethyl, a acetoxyethyl and a pivaloyloxyethyl groups alkoxycarbonyloxyalkyl groups, such as ethoxycarbonyloxymethyl and a ethoxycarbonyloxyethyl dialkylaminoalkyl groups such as dimethylaminomethyl, dimethylaminoethyl, or diethylaminoethyl and lactone groups such as phthalidyl or dimethoxyphthalidyl. It is realised that in the compounds of this invention the hydrogen atoms at the C 5 and C 6 carbon atoms may be in the cis or trans configuration preferably the hydrogen atoms at the C 5 and C 6 carbon atoms will be in the trans configuration with the configuration 5R, 6S. When in the cis configuration the preferred stereochemistry is 5R,6R. It is further realised that the carbon atom assigned as C S is also a centre of optical activity and may exist in either the R or S stereochemical configuration. Most suitably the C 8 carbon atom will be in the R configuration. Those R2 substituents containing a double bond may be present in the E or Z configuration, for example, R2 may suitably be E acetamidoethenyl and Z acetamidoethenyl. One preferred sub group of compounds within the scope of the present invention is the compound of formula II or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI6.1 wherein R1 is as defined hereinbefore with respect to formula I and B is a divalent radical of structure EMI7.1 wherein R3 represents a carboxylic acid group or an ester or amide derivative thereof or a nitrile group and R4 represents hydrogen, an optionally substituted hydrocarbon or heterocyclic group, a carboxylic acid group or an ester or amide derivative thereof or a nitrile group. The radicals R and R may be the same or different and each is suitably a carboxylic acid or an ester group CO2P5 wherein P is an alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heterocyclic or heterocyclyl alkyl group, any of which may be substituted. Suitable such R5 groups include the C1 6 alkyl group such as methyl, ethyl, n or iso propyl, n , sec , tert , or iso butyl, or substituted C16 alkyl wherein the substituent is an amino group or a protected amino group, such as for example p nitrobenzyloxycarbonylamino. Preferably R is a carboxylic acid group, or a salt, or methyl, ethyl, p nitrobenzyl, 2 amino ethyl or 2 p nitrobenzyloxycarbonylamino ethyl ester thereof.Preferably R4 is hydrogen. Particular compounds within the scope of the present invention include sodium 5R,6S 3 2 acetamidoethylthio 6 R 1 4,5 dimethoxycarbonyltriazol 1 yl ethyl 7 oXo 1 azabicyclo 3.2.0. hept 2 ene carboxylate disodium 5R,6S 3 2 acetamidoethylthio 6 R 1 4 carboxytriazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate. sodium 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 4,5 dimethoxycarbonyltriazol 1 yl ethyl 7 oxo l azabicyclo 3.2.0. hept 2 ene 2 carboxylate. disodium 5R,6S 3 E 2 acetamidoethenylthio 6 E R 1 4 carboxytriazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.0. 3 hept 2 ene 2 carboxylate. 5R,6S 3 E 2 acetamidoethylthio 6 R 4 2 aminoethyloxycarbonyl triazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.0. hept 2 ene 2 carboxylic acid. The compounds of the formula I may be employed in the treatment of bacterial infections, such as those due to Staphylococcus aureus, Escherichia coli and Klebsiella aerogenes. Thus the present invention provides a pharmaceutical composition which comprises a compound of the formula I and a pharmaceutically acceptable carrier. The compositions may be formulated for administration by any route, such as oral topical or parenteral. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine, tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica disintegrants, for example potato starch or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia non aqueous vehicles which may include edible oils , for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol preservatives, for example methyl or propyl hydroxy benzoate or sorbic acid, and if desired conventional flavouring or colouring agents. Suppositories will contain conventional suppository bases, e.g. cocoa butter or other glyceride. For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vaccuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. Unit dose forms according to this invention will normally contain from 50 to 500 mgs of a compound of this invention, for example about 62.5, 100, 125, 150, 200, 250 or 300 mgs. Such compositions may be administered from 1 to 6 times a day or more conveniently 2, 3 or 4 times a day so that the total daily dose for a 70kg adult is about 200 to 2000 mgs, for example about 400, 600, 750, 1000 or 1500 mgs. The compositions of this invention may be used to treat infections of the respiratory tract, urinary tract or soft tissues in humans, or mastitis in cattle. The present invention also provides synergistic pharmaceutical compositions which comprise a pharmaceutical composition as hereinbefore described which also contains a penicillin or a cephalosporin. Suitable penicillins for inclusion in the compositions of this invention include benzyl penicillin, phenoxymethyl penicillin, ampicillin, or a pro drug therefor, amoxycillin, or a pro drug therefor, carbenicillin or a pro drug therefor, ticarcillin or a pro drug therefor, suncillin, sulbenicillin, azlocillin, mezlocillin, piperacillin or apalcillin. Particularly suitable penicillins for inclusion in orally administrable compositions of this invention include ampicillin and its orally administrable pro drugs, amoxycillin and its orally administrable pro drugs and orally administrable pro drugs or carbenicillin. Thus particularly suitable penicillins include ampicillin anhydrate, ampicillin trihydrate, sodium ampicillin, talampicillin hydrochloride, pivampicillin hydrochloride and bacampicillin hydrochloride amoxycillin trihydrate, sodium amoxycillin and the sodium salts of the phenyl and 5 indanyl a esters of carbenicillin. A preferred penicillin for inclusion in the orally administrable compositions of this invention is amoxycillin trihydrate. A further preferred penicillin for inclusion in the orally administrable compositions of this invention is ampicillin trihydrate. Particularly suitable penicillins for inclusion in injectably administrable compositions of this invention include injectable salts, such as the sodium salt of ampicillin, amoxycillin, carbenicillin and ticarcillin. A preferred penicillin for inclusion in the injectably administrable compositions of this invention is sodium amoxycillin. A further preferred penicillin for inclusion in the injectably administrable compositions of this invention is sodium ampicillin. Particularly suitable cephalosperins for inclusion in the compositions of this invention include cephaloridine, cephalexin, cephradine, cefazolin and cephalothin. A particularly suitable cephalosporin for inclusion in the orally administrable compositions of this invention is cephalexin. Particularly suitable cephalosporins for inclusion in the injectably administrable compositions of this invention include cephaloridine, cefazolin and cephradine, generally as their pharmaceutically acceptable salt. The weight ratio ibetween compound of this invention and penicillin or cephalosporin is generally between from 10 1 to 1 10, more usually from 5 1 to 1 5 and normally from 3 1 to 1 3. The penicillin or cephalosporin is generally utilised in its conventionally administered amount. The invention also provides a method of trcntci,t of bacterial infections in animals including man which comprises the administration of an antibacterially effective amount of a compound of the invention. The present invention also provides a process for the preparation of a compound of the formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises reacting a compound of formula III EMI13.1 wherein RÚ is as defined with respect to formula I and wherein any reactive groupe may be protected and Rx is a carboxy protecting group. with a dipolarophile and thereafter where necessary carrying out one or more of the following steps i removing any protecting groups on R , or the dipolarophile, ii removing the carboxy protecting group Rx iii converting a free acid to an in vivo hydrolysable ester or a phrmaceutically acceptable salt.Suitably the reaction is performed at an elevated 0 temperature ie in the range 50 150 C. Conveniently the reaction is performed at the reflux temperature of the solvent employed in the reaction. Suitable solvents include aromatic hydrocarbons such as, for example, benzene and toluene, paraffins, and ethers such as tetrahydrofuran. The course of the reaction may be followed by conventional methods such as thin layer chromatography and terminated when an optimum quantity of product is present in the reaction mixture. When used herein the term dipolarophile indicates an optionally substituted alkene, alkyne, nitrile, imine, and wherein any reactive substituents may be protected. Suitably at least one substituent on the dipolarophile will be a conjugating group. Preferably the dipolarophile will be a compound of formula IV R C C R4 IV wherein R3 and R are as defined with respect to formula II and wherein any reactive groups may be protected. Suitably carboxyl blocking derivates for the group CO2Rx in formula III include ester derivates of the carboxylic acid. The derivative is preferably one which may readily be cleaved at a later stage of the reaction. Suitable ester forming carboxyl blocking groups are those which may be removed under conventional conditions. Such groups for Rx include benzyl, p methoxybenzyl, 2,4, 6 trimethylbenzyl, 3,5 di t butyl 4 hydroxy benzyl, benzoylmethyl, p nitrobenzyl, e nitrobenzyl, 4 pyridylmethyl, 2,2,2 trichloroethyl, 2,2, 2 tribromoetbyl, acetonyl, t amyl, diphenylmethyl, triphenylmethyl, adamantyl, 2 benzyloxyphenyl, 4 methylthiophenyl, tetrahydrofur 2 yl, tetrahydropyran 2 yl, pentachlorophenyl, p toluenesulphonylethyl, methoxymethyl, or an in vivo hydrolysable ester radical such as defined above. A preferred group Rx in the p nitrobenzyl group. The carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular RX group, for example, acid and base catalysed hydrolysis, or by enzymically catalysed hydrolysis, or by hydrogenolysis. The starting material of formula III having sub formula V EMI15.1 wherein R1 is a defined with respect of formula I and wherein any reactive groups may be protected and Rx is hydrogen or a carboxy blocking group are disclosed in U.K. Patent Application No. 8034453. The starting material of formula III having sub formula VI EMI16.1 wherein R1 is as defined with respect to formula I and wherein any reactive groups may be protected, R is hydrogen or a carboxy blocking group, and R6 is an azido group may be prepared by a process which comprises the reaction of a compound of the formula VII EMI16.2 wherein RÚ is as hereinbefore defined, OR4 is a displaceable group, and R is a hydrogen atom or a carboxyblocking group with an azide, and thereafter if necessary removing any carboxy blocking group. Suitably the azide is present in the form of an inorganic azide such as sodium azide or lithium azide, or as an organic azide such as tetramethylguanidium azide.Care must be exercised when selecting an appropriate azide as many azides, particularly heavy metal azides are explosive. Suitably OR7 is a readily displaceable group such as a sulphonate ester for example p nitrobenzenesulphonate or trifluoromethylsulphonate. The reaction is performed in an inert organic solvent which is preferably aprotic and unreactive towards the reagents involved. Suitable solvents include dimethylformamide. In addition to utility as an intermediate the compound of formula VII wherein Rx represents hydrogen are of use in the treatment of bacterial infection.Reduction of the azido group R6 leads to compounds also of use in the treatment of bacterial infection. Accordingly the present invention also provides a compound of formula VIII or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI17.1 wherein R1 is as defined with respect to formula I 8 and R is an azido or amino group. Suitably R8 is azido. Preferably R8 is amino. A compound of the formula VIII wherein R8 is an azido group may be converted to a compound of the formula VIII whErein R is an amino group by standard reduction methods, such as catalytic hydrogenation, for example using a transition metal catalyst such as palladium suitably palladium on carbon. The present invention further provides a pharmaceutical composition which comprises a compound of formula VIII and a pharmaceutically acceptable carrier. The following Examples illustrate the present invention. Example 1 p Nitrobenzyl 5R.6R 3 E 2 acetamidoethenylthio 6 S l p nitrobenzenesulphonyloxyethyl 1 7 oxo l azabicyclor3. 2.0 hept 2 ene 2 carboxylate EMI19.1 p Nitrobenzyl 5R,6R 3 E 2 acetamidoethenylthto 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate el 0.500 gm was dissolved in dry tetrahydrofuran 125 ml and cooled to OOC. N Methylmorpholine 0.452 gm , 4 dimethylaminopyridine 0.100 gm and p nitrobenzenesulphonyl chloride 1.00 gm were added to the solution which was then stirred at room temperature for 18 hours. The solvent was removed at reduced pressure and the residue partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium chloride solution and dried over anhydrous magnesium sulphate.Removal of the solvent at reduced pressure gave a pale yellow oil, which was chromatographed over silica gel 25 gm . Elution with ethyl acetate gave the title compound e2 as a pale yellow oil 89 mg .Crystallisation from chloroform afforded a white solid 56 mg , max EtOH 321 nm m 13887 , 254 nm m 24698 , max CHCl3 3420, 1775, 1699, 1620, 1608, 1522, 1351 cm bH CDC13 1.48 3H, d, CH3CH , 2.13 3H, s, COCH3 , 3.03.4 2H, ABX, 4 CH2 , 3.81 1H, dd, J68 9.2 Hz, J56 5.8Hz, 6 CH , 4.2 4.4 1H, dt, 5 CH , 5.1 5.25 1H, m, 8 CH , 5.36 2H, AB, CH2Ar , 5.89 1H, d, S CH C , 7.31 1H, dd,C CH NH , 7.59 d, aromatic protons , 8.08 d, aromatic protons , 8.20 d, aromatic protons , 8.41 d, aromatic protons , m e relative intensity 429.0965 C20H19NOS requires 429.0982 , 203 20 , 60 100 , 57 70 . Further elution with 25 ethanol ethyl acetate gave unreacted starting material as a white solid from ethyl acetate 300 mg . Example 2 p Nitrobenzvl 5R,6R 3 E 2 acetamidoethenylthio 6 R 1 azidoethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylateEMI21.1 The p nitrobenzenesulphonate e2 56 mg was dissolved in dry dimethylformamide 2 ml and stirred with sodium azide 6.9 mg for 2 hours at room temperature.The solvent was removed at reduced pressure and the residue partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulphate and the solvent removed at reduced pressure to yield a yellow oil.This oil was chromatographed over silica gel 10 gm .Elution with a gradient of 0 2 ethanol chloroform gave the title compound e3 as a white solid, which was digested in ethyl acetate ether and collected by filtration 7 mg , v max CHCl3 3420, 2125, 1775, 1700, 1620, 1521, 1350, 1330 cm 1, max EtOH 322 nm m 16212 , 262 nm m 17128 , H CDCl3 1.43 3H, d, CH3CH , 2.09 3H, s, COCH3 , 2.9 3.35 2H, ABX, 4 CH2 , 3.61 1H, t,J68 6.8 Hz, 6 CH , 3.87 1H, apparent quintet, 8 CH , 4.25 1H, dt, J56 6.0 Hz, 5 CH , 5.38 2H, AB, CH2Ar , 5.94 1H, d, S CH C , 7.25 1H, dd, C CH N , 7.65 3H, broad res. d, NH aromatic protons , 8.22 2H, d, aromatic protons , m e relative intensity 472 1 , 429 5 , 361 5 , 249 5 , 207 5 , 183 8 , 136 15 , 106 15 , 84 100 . EXAMPLE a p Nitrobenzyl 5R,6S 3 2 acetamidoethylthio 6 R 1 4,5 dimethoxycarbonyltriazol 1 yl ethyls 7 oxo 1 azabicyclo 3.2.o.3 hept 2 ene 2 carboxylateEMI23.1 p Nitrobenzyl 5R,6S 3 2 acetamidoethylthio 6 R 1azidoethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 55mg 0.116mM was suspended in dry toluene 15ml and heated to reflux for 6 hours with dimethyl acetylenedicarboxylate 33mg 0.232mM . The solution was then cooled to room temperature and the precipitated solid collected by filtration, washing with toluene, ethyl acetate and ether.The title compound was obtained as a pale yellow needle shaped crystalline solid 51mg max CH3CN 318nm ml13200 , 267 nm ml11626 , vmax KBr 3400, 1780, 1730, 1705, 1655, 1608, 1548, 1522, 1350, 1335cm 1, dH d7 DMF 8.28 2H,d, aromatic protons , 7.81 2H,d, aromatic protons , 5.2 5.7 3H,m,CH2Arl8 CH , 4.02 3H,S,CO2CH3 , 3.93 3H,S,CO2CH3 , 1.87 3H,S,COCH3 , 1.76 3H,d,J 6.5Hz, CH3CH , m e relative intensity 431 3 , 363 20 , 304 75 , 154 80 , 124 50 , 86 100 . b Sodium 5R,6S 3 2 acetamidoethylthio 6 R 1 4,5 dimethoxycarbonyltriazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.o. hept 2 ene 2 carboxylate.EMI24.1 The ester e2 15mg was suspended in 30 aqueous 1,4 dioxan 15ml and shaken for 3.5 hours with hydrogen in the presence of 5 palladium on carbon catalyst 23mg , at ambient temperature and pressure. Sodium bicarbonate 2.lmg was added and the suspension filtered over celite, washing well with water 25ml . The filtrate was concentrated to approximately 2Oml at reduced pressure and washed with ethyl acetate 3 x 50ml . The resulting aqueous solution was estimated to contain 7.3mg of the title compound e6 based on elm8,000 at Amax 295nm in the ultra violet spectrum. EXAMPLE 4 a p Nitrobenzyl 5R,6S 3 2 acetamidoethylthio 6 R 1 4 2 nitrobenzyloxycarbonyltriazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.e. hept 2 ene 2 carboxylate and 2 nitrobenzyl 5R,6S 3 2 acetamidoethylthio 6 R 1 5 p nitrobenzyloxycarbonyl triazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.0. hept 2 ene 2 carboxylate.EMI25.1 The azido derivative e4 60mg 0.127mM was suspended in dry tol ene 15ml and refluxed for 3 hours with p nitrobenzyl propiolate 52mg,0.253mM , during which time the cycloaddition products crystallised out of solution. The white solid 48mg was collected by filtration, Amax CH3CN 316nm ml3320 , 267nm m20406 , vmax KBr 3400, 1778, 1738, 1700, 1660, 1608, 1520, 1350cm 1, dH d6 acetone 8.82 1H,s, triazolyl CH , 8.25 2xd, 4H, aromatic protons , 7.79 4H,d, aromatic protons , 7.38 1H, broad resonance, NH , 5.28 5.63 5H, AB s m, 2xCH2Ar 8 CH , 4.27 1H,dt,5 CH , 4.10 1H, dd, J56 2.9Hz, J68 8.8Hz, 6 CH , 3.28 3.52 m,NCH2 4 CH2 , 2.9 3.1 2H,m, SCH2 , 1.86 3H,s, COCH3 , 1.82 3H,d,CH3CH . Additional signals at 8.36 S, triazolyl CH and 1.77 d, CH3CH in the N.M.R.spectrum indicated the presence of the minor isomer e8 15 . b Disodium 5R,6S 3 2 acetamidoethylthio 6 R 1 4 carboxytriazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.0. hept 2 ene 2 carboxylate.EMI27.1 The diester e7 12mg was suspended in 30 aqueous 1,4 dioxan 15ml and shaken for 3.5 hours with hydrogen in the presence of 5 palladium on carbon catalyst 18mg at ambient temperature and pressure. Sodium bicarbonate 3mg was added and the suspension filtered oker Celite, washing well with water 25ml . The filtrate was concentrated to approximately 20ml at reduced pressure and washed with ethyl acetate 3 x 50ml . The resulting aqueous solution was estimated to contain 6.0mg of the title compound e9 based on m8,000 at max 299nm in the ultra violet spectrum. Example 5 a p Nitrobenzyl 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 4,5 diemthoxycarbonyltriazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylateEMI28.1 p Nitrobenzyl 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 azidoethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 60 mg 0.127 mM was suspended in dry toluene 15 ml and refluxed for 3 hours with dimethylacetylenedicarboxylate 36 mg 0.254 mM . The solution was cooled to room temperature and the resulting precipitate collected by filtration. This solid was purified by column chromatography over silica gel 2 gm .Elution with ethyl acetate afforded the title compound as a white solid, which was digested in dry diethyl ether and collected by filtration 15 mg , v mav KBr 3400, 1780, 1730, 1700, 1620 cm 1, max CH3CN 323 nm Em 16,610 , 262 nm Em 18,090 , 217 nm 24,775 , H d7 DMF 10.48 1H, d,NH , 8.31 2H, d, aromatic protons , 7.84 2H, d, aromatic protons , 7.21 1H, q, C CHNH , 5.98 1H, d,C CH S 5.3 5.7 3H, ABq m, CH2Ar 8 CH , 4.38 1H, dd,J 2.9Hz and 10.0 Hz 6 CH , 4.21 1H, dt, 5 CH , 4.06 3H,S, CO2CH3 3.97 3H, S, C02CH3 , 3.27 2H, ABX, 4 CH2 , 2.03 3H, S, COCH3 , 1.78 3H, d, CH3CH , m e relative intensity 361 6 , 207 12 , 154 78 , 124 33 , 84 100 . b Sodium 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 4,5 dimethoxycarbonyltriazol 1 yl ethyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylateEMI29.1 The ester ell 5 mg was hydrogenolysed by the procedure described in Example 3b to yield an aqueous solution containing the title compound e12 2 mg , max M2O 307 nm, 224 nm. Example 6 a p Nitrobenzyl 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 4 p nitrobenzyloxycarbonyltriazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylateEMI30.1 The azido derivative elO 60 mg 0.127 mM was suspended in dry toluene 10 ml and refluxed for 3 hours with p nitrobenzyl propiolate 52 mg 0.253 mM .The solution was then allowed to cool and the precipitate collected by filtration, washing well with toluene. The resulting solid 38 mg was digested in chloroform acetonitrile and re filtered, washing with dry diethyl ether. The title compound el3 19 mg was obtained as a white solid, max KBr 3400, 1780, 1730, 1698, 1620, 1610 cm 1, max CH3CN 323 nm Em 16,970 264 nm Em 26,340 215 nm Em 32,890 bH d7 DMP 10.48 1H, d, NH 9.12 lH, S, triazole CH , 8.32 4H, 2 x d, aromatic protons 7.83 4H, d, aromatic protons , 7.20 1H, dd, C CH N , 5.98 1H, d, C CH S , 5.3 5.7 5H, q s m, aromatic protons 8 CH , 4.25 2H, dd m, J56 3.0Hz, J68 8.9 Hz, 6 CH 5 CH , 3.28 2H, ABX, 4 CH2 , 2.02 3H, S, COCH3 , 1.81 3H, d, CH3CH . b Disodium 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 4 carboxvtriazol l vl ethYl 7 oxo l azabicvclo r3.2.0.1 hept 2 ene 2 carboxylateEMI31.1 The ester e13 6 mg was hydrogenolysed by the procedure described in Example ib to yield an aqueous solution containing the title compound elS . This solution was estimated to contain 3.0 mg product based on Em 14,000 at A max 309 nm in the u.v. spectrum. Example 7 a p Nitrobenzyl 5R,6S 3 E 2 acetamidoethenylthio 6 R w 4 2 p nitrobenzvloxvearbonylamino3ethvloxv carbonyl triazol 1 yl ethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate EMI32.1 The azido derivative elO 60 mg 0.127 mM was suspended in dry toluene 50 ml and refluxed for 24 hours with 2 N p nitrobenzyloxycarbonyl aminoethyl propiolate 54 mg 0.185 mM . The solvent was then removed at reduced pressure and the resulting pale yellow solid was purified by column chromatography over silica gel 4 gm .Elution with 5 ethanol ethyl acetate gave the title compound el4 as a white solid. This solid was digested in dry diethyl ether and collected by filtration 17 mg , s max CHBr3 3300 3400 broad , 1775, 1680 1720 broad , 1618, 1602, 1518, 1342 cm , max CH3CN 322 nm Em 15,605 , 265 nm Em, 26,275 , 215 nm Em 33,890 , bH . d7 DMF 10.47 lH, .d, NH , 8.96 1H, s, triazole CH , 8.30 4H, 2 x d, aromatic protons , 7.83 2H, d, aromatic protons , 7.68 3H, d broad res., aromatic protons NH , 7.20 1H, dd, C CH NH , 5.97 1H, d, C CH S , 5.32 5.62 3H, q m, C2Ar 8 CH , 5.28 2H,S, CH2Ar , 4.42 2H, t, CO2CH2 , 4.18 4.38 2H, dt dd,J562.5Hz,.J68 8.0Hz, 5 CH 6 CH , 3.56 q, CH2CH2NH , 3.28 2H, ABX, 4 CH2, J4a5 9.75 Hz, J 4b5 8.5 Hz, J 4a4b 18.25 Hz , 2.03 3H, s, COCH3 , 1.79 3H, d, CH3CH . b 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 4 2 aminoethyloxycarbonyl triazol 1 yl ethyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylic acidEMI34.1 A solution of the ester e14 6 mg in 1,4dioxan 5 ml , water 0.75 ml and 0.05 M phosphate buffer 1 ml was hydrogenated in the presence of 5 palladium on carbon catalyst 12 mg for 3 hours. The suspension was then filtered over Celite, washing with water 15 ml . The filtrate was concentrated to approximately 15 ml and washed with ethyl acetate 3 x 25 ml . The resulting aqueous solution was estimated to contain 1.9 mg of the title compound e16 based on Em 14,000 at A max 308 nm in the u.v.spectrum. Example 8 5R,6S 3 E 2 acetamidoethenylthio 6 R 1 aminoethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acidEMI35.1 The azido derivative e3 4 mg was dissolved in 1,4 dioxan 4 ml , water 0.6 ml and pH 7.0, 0.05 M phosphate buffer 0.75 ml and shaken with hydrogen for 2 hours in the presence of 5 palladium on carbon 8 mg .The suspension was filtered over Celite, washing well with water 25 ml . The filtrate was concentrated to approximately 20 ml and washed with ethyl acetate 3 x 50 ml . The aqueous solution was further concentrated to about 5 ml and chromatographed over Biogel P2, eluting with water. Fractions containing the title compound el7 were identified by the chromophore at A max H20 300 nm in the uv spectrum and were combined to yield an aqueous solution of the product 0.67 mg , max H20 300 nm, 226 nm. BIOLOGICAL DATAEMI36.1 tb SEP ORGANISM SEP COMPOUND SEP OF tb EXAMPLE SEP NO. SEP 4 SEP 6 SEP 7 tb MIC SEP g ml SEP MIC SEP g ml SEP MIC SEP g ml tb SEP BrothÚ SEP BrothÚ SEP BrothÚ tb SEP Citrobacter SEP freundii SEP EB SEP 1.6 SEP 25 SEP 0.8 tb SEP Enterobacter SEP cloacae SEP Nl SEP 1753 SEP 3.1 SEP 25 SEP 1.6 tb SEP Escherichia SEP coli SEP 0111 SEP E8 SEP 3.1 SEP 12.5 SEP 1.6 tb SEP Escherichia SEP coli SEP JT39 SEP E96 SEP 3.1 SEP 3.1 SEP 0.8 tb SEP Escherichia SEP coli SEP ESS SEP 1.6 SEP 1.6 SEP 0.8 tb SEP Klebsiella SEP aerogenes SEP A SEP T767 SEP 3.1 SEP 1.6 SEP 3.1 tb SEP Proteus SEP mirabilis SEP 977 SEP 13 SEP 12.5 SEP 12.5 SEP 25 tb SEP Proteus SEP morganii SEP 1580 SEP 25 SEP 12.5 tb SEP Proteus SEP rettgeri SEP WM16 SEP 6.2 SEP 3.1 SEP 6.2 tb SEP Proteus SEP vulgaris SEP WO91 SEP 6.2 SEP 12.5 SEP 25 tb SEP Pseudomonas SEP aeruginosa SEP A SEP 11 SEP 100 SEP 50 SEP 100 tb SEP Salmonella SEP typhimurium SEP CT10 SEP . SEP 6.2 SEP 1.6 SEP 1.6 tb SEP Serratia SEP marcescens SEP US20 SEP 6.2 SEP 6.2 SEP 3.1 tb SEP Shigella SEP sonnei SEP MB11967 SEP .12.5 SEP 3.1 SEP 1.6 tb SEP Bacillus SEP subtilis SEP A SEP 3.1 SEP 6.2 SEP 0.8 tb SEP Staphylococcus SEP aureus SEP Oxford SEP 6.2 SEP . SEP 6.2 SEP 0.4 tb SEP Staphylococcus SEP aureus SEP Russell SEP MB9 SEP 6.2 SEP 6.2 SEP 0.4 tb SEP Staphylococcus SEP aureus SEP 1517 SEP 100 SEP 25 SEP 12.5 tb SEP Streptococcus SEP faecalia SEP I SEP 100 SEP 100 SEP 50 tb SEP Streptococcus SEP pneumoniae SEP CN33 SEP 1.6 SEP NG SEP NG tb SEP Streptococcus SEP pyogenes SEP CN10 SEP 1.6 SEP NG SEP 0.4 tb